[go: up one dir, main page]

MX2016009167A - Metodo de tratamiento basado en combinacion. - Google Patents

Metodo de tratamiento basado en combinacion.

Info

Publication number
MX2016009167A
MX2016009167A MX2016009167A MX2016009167A MX2016009167A MX 2016009167 A MX2016009167 A MX 2016009167A MX 2016009167 A MX2016009167 A MX 2016009167A MX 2016009167 A MX2016009167 A MX 2016009167A MX 2016009167 A MX2016009167 A MX 2016009167A
Authority
MX
Mexico
Prior art keywords
combination
treatment method
based treatment
inhibitor
administering
Prior art date
Application number
MX2016009167A
Other languages
English (en)
Other versions
MX386070B (es
Inventor
Deborah H Charych
Ute Hoch
Marie BURNS Nancy
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016009167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2016009167A publication Critical patent/MX2016009167A/es
Publication of MX386070B publication Critical patent/MX386070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere (entre otras cosas) a un método, que comprende las etapas de (a) administrar a un paciente una cantidad inhibidora de PARP de un inhibidor de PARP; y (b) administrar al paciente una cantidad inhibidora de topoisomerasa I de un inhibidor de topoisomerasa I de larga acción.
MX2016009167A 2014-01-14 2015-01-13 Metodo de tratamiento basado en combinacion. MX386070B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927376P 2014-01-14 2014-01-14
US201462080775P 2014-11-17 2014-11-17
PCT/US2015/011239 WO2015108876A1 (en) 2014-01-14 2015-01-13 Combination-based treatment method

Publications (2)

Publication Number Publication Date
MX2016009167A true MX2016009167A (es) 2016-09-09
MX386070B MX386070B (es) 2025-03-18

Family

ID=52469293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009167A MX386070B (es) 2014-01-14 2015-01-13 Metodo de tratamiento basado en combinacion.

Country Status (8)

Country Link
US (2) US10653689B2 (es)
EP (1) EP3094331B1 (es)
JP (1) JP6758195B2 (es)
KR (1) KR102501566B1 (es)
AU (1) AU2015206667B2 (es)
CA (1) CA2934552C (es)
MX (1) MX386070B (es)
WO (1) WO2015108876A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611382B1 (ko) 2018-09-19 2023-12-07 삼성디스플레이 주식회사 터치 감지 유닛과 그를 포함하는 표시 장치
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414017B8 (pt) * 2003-09-17 2021-05-25 Nektar Therapeutics Al Corp pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
JP2006124351A (ja) 2004-11-01 2006-05-18 Yakult Honsha Co Ltd 徐放性抗腫瘍剤組成物
CN101370497B (zh) 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
WO2007092646A2 (en) 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
CA2705537A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20090149397A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
KR101779229B1 (ko) 2009-11-18 2017-09-18 넥타르 테라퓨틱스 다중 팔 중합체-약물 콘쥬게이트의 염 형태
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Also Published As

Publication number Publication date
AU2015206667A1 (en) 2016-07-07
US20200237747A1 (en) 2020-07-30
AU2015206667B2 (en) 2020-05-14
US20160339013A1 (en) 2016-11-24
US10653689B2 (en) 2020-05-19
CA2934552A1 (en) 2015-07-23
JP6758195B2 (ja) 2020-09-23
WO2015108876A1 (en) 2015-07-23
JP2017502091A (ja) 2017-01-19
EP3094331A1 (en) 2016-11-23
EP3094331B1 (en) 2017-12-27
CA2934552C (en) 2021-03-30
MX386070B (es) 2025-03-18
KR102501566B1 (ko) 2023-02-17
KR20160106086A (ko) 2016-09-09

Similar Documents

Publication Publication Date Title
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
EA201691582A1 (ru) Новые фармацевтические препараты
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
GEAP201914307A (en) 4'-substituted nucleosidederivatives as hiv reverse transcriptase inhibitors
CL2016002971A1 (es) Combinación.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2021010460A (es) Metodo de tratamiento con tradipitant.
MX2016013950A (es) Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica.
CR20150440A (es) Nuevos derivados de piridina
MX2023006415A (es) Anticuerpos, usos y metodos.
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CR20160459A (es) Nuevos derivados de piridina
CR20160448A (es) Nuevos derivados de piridina
CL2018001493A1 (es) Nuevos derivados de fenilo
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
UY35747A (es) Derivados sustituidos de fenilalanina
EA201692534A1 (ru) Способы лечения гипотонии
CO2017005732A2 (es) Compuestos de dihidropirimidin-2-ona y sus usos médicos
UY35745A (es) Derivados sustituidos de fenilalanina
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
UY35823A (es) Profármacos de antagonista de nmda
AR102871A1 (es) Métodos de tratamiento de fibrosis
MX2016002307A (es) Tratamiento para el cancer.